Cooper-Standard Q2 Sales Rise, but Costs Drag EBITDA: H2 Recovery Plan in Spotlight

What happened

Cooper-Standard reported higher second-quarter sales but lower adjusted EBITDA, as material inflation, tariffs, and other cost pressures outweighed operational savings. Management expects commercial recoveries and continued cost actions to improve results in the second half while maintaining its full-year sales and profitability plan. The Q2 EBITDA miss underscores the ongoing tension between internal cost-out efforts and external cost headwinds that have already pressured margins. The maintained guidance places a higher burden on H2 execution, particularly on commercial recoveries and lean savings, to hit the $260–$300M adjusted EBITDA target. While the refinanced balance sheet provides breathing room, the equity story now hinges more clearly on converting cost actions into cash flow before the first large cash interest payment in November 2026.

Implication

The Q2 earnings call reveals that cost headwinds are still overwhelming operational savings, making the back-half recovery plan pivotal. Investors should watch for concrete evidence of commercial recoveries in Q3 and Q4 to verify the guidance. Without rapid margin improvement, the $260–$300M EBITDA target looks aggressive, which could pressure liquidity and the stock. The maintained guidance prevents a thesis break for now, but the margin for error is thinning. We stand by the WAIT rating, as the next two quarters will define whether the turnaround stays on track.

Thesis delta

The Q2 EBITDA shortfall confirms that inflationary and tariff pressures are proving stickier than the cost-out benefits in the near term. This shifts the thesis to a more execution-dependent second-half recovery, where the maintained full-year guidance now requires a material step-up in commercial recoveries and cost actions. The risk of an EBITDA guidance miss has increased modestly, but the refinancing backdrop still provides a runway to demonstrate cash conversion.